HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M600018-JLR200v1 47/6/1274    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nguyen, M. N. Articles by Barrett, P. H. R. Search for Related Content PubMed PubMed Citation Articles by Nguyen, M. N. Articles by Barrett, P. H. R. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 47, 1274-1280, June 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma

Minh N. Nguyen, Dick C. Chan, Kevin P. Dwyer, Paul Bolitho, Gerald F. Watts and P. Hugh R. Barrett¹

Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia

Published, JLR Papers in Press, March 23, 2006.

¹ To whom correspondence should be addressed. e-mail: hugh.barrett{at}uwa.edu.au

Apolipoprotein C-III (apoC-III) is an important regulator of lipoprotein metabolism. Radioisotope and stable isotope kinetic studies show differing results in relation to the kinetics of apoC-III in HDL. Kinetic analysis of HDL apoC-III may be difficult because of its low concentration, as well as the presence of other apoproteins at higher concentration, in the HDL fraction. We used Intralipid® (IL), known to preferentially extract apoC proteins from plasma, as a means of extracting apoC-III from HDL before apoprotein separation by isoelectric focusing gel electrophoresis for the measurement of tracer enrichment. Protein purity was assessed by an isoleucine-to-leucine (Ile/Leu) ratio, as apoC-III contains no isoleucine. We compared apoC-III kinetics in 14 men using a bolus infusion of deuterated leucine. The Ile/Leu ratio for IL-extracted HDL (IL-HDL) apoC-III (3.0 ± 0.7%) was not different from that of VLDL apoC-III (2.6 ± 0.6%) but was significantly lower than that of untreated HDL apoC-III (9.0 ± 2.9%) (P < 0.001). The isotopic enrichment curves and fractional catabolic rates (FCRs) for IL-HDL apoC-III were not different from those of VLDL apoC-III. In contrast, HDL apoC-III had significantly lower isotopic enrichments and FCRs than IL-HDL apoC-III (P < 0.001). In conclusion, this simple IL method can be used to isolate apoC-III from HDL with minimal interference from other HDL apoproteins, and it demonstrates that the kinetics of apoC-III in VLDL and HDL are similar, supporting the concept of a single kinetically homogeneous pool of apoC-III in plasma.

Supplementary key words high density lipoprotein • very low density lipoprotein • gas chromatography-mass spectrometry • lipoprotein metabolism • apolipoprotein C-III

Abbreviations: apoC-III, apolipoprotein C-III; d₃-leucine, deuterated leucine; FCR, fractional catabolic rate; IEF, isoelectric focusing; IL, Intralipid®; Ile/Leu, isoleucine-to-leucine; PR, production rate; PVDF, polyvinylidene difluoride; TRL, triglyceride-rich lipoprotein; TTR, tracer-to-tracee ratio

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. C Chan, M. N Nguyen, G. F Watts, E. M. Ooi, and P H. R Barrett Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity Am. J. Clinical Nutrition, April 1, 2010; 91(4): 900 - 906. [Abstract] [Full Text] [PDF]

				C. O. Mendivil, C. Zheng, J. Furtado, J. Lel, and F. M. Sacks Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 239 - 245. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, E. M.M. Ooi, J. Ji, A. G. Johnson, and P. H. R. Barrett Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1831 - 1837. [Abstract] [Full Text] [PDF]

				E. M.M. Ooi, G. F. Watts, D. C. Chan, M. M. Chen, P. J. Nestel, D. Sviridov, and P. H. R. Barrett Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome Diabetes Care, August 1, 2008; 31(8): 1656 - 1661. [Abstract] [Full Text] [PDF]

				D. C. Chan, M. N. Nguyen, G. F. Watts, and P. H. R. Barrett Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 557 - 564. [Abstract] [Full Text] [PDF]

				C. Zheng, C. Khoo, K. Ikewaki, and F. M. Sacks Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions J. Lipid Res., May 1, 2007; 48(5): 1190 - 1203. [Abstract] [Full Text] [PDF]

				P. H. R. Barrett, D. C. Chan, and G. F. Watts Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans J. Lipid Res., August 1, 2006; 47(8): 1607 - 1619. [Abstract] [Full Text] [PDF]